Antibody humanization is a process that involves minimizing the presence of non-human amino acid residues in order to improve the physicochemical and biological properties of the molecule, as well as to generate intellectual property.

These objectives are achieved through the innovative GlobalBio HumanizationTM Method (GBM). The process begins with a rigorous analysis of the sequence to be modified in order to achieve an antibody with the desired therapeutic characteristics.